Cellectar awarded $2.0 million phase ii nih sbir grant to support pivotal study of iopofosine i-131 in waldenstrom's macroglobulinemia

Florham park, n.j., aug. 18, 2021 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a peer-reviewed national institutes of health (nih) phase ii small business innovation research (sbir) grant of approximately $2 million from the national cancer institute (nci).
CLRB Ratings Summary
CLRB Quant Ranking